Evidence map›Paper›PMID 39465396›Full record

ArticleRadiation oncology (London, England)2024

Influence of brain metastases on the classification, treatment, and outcome of patients with extracranial oligometastasis: a single-center cross-sectional analysis.

Sebastian M Christ, Gabriel W Thiel, Philip Heesen, Siyer Roohani, Michael Mayinger, Jonas Willmann, Maiwand Ahmadsei, Urs J Muehlematter, Alexander Maurer, Josef A Buchner and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiation oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Brain metastasis: Opportunities for novel therapies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Sebastian M ChristDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Rämistrasse 100, Zurich, 8091, Switzerland. sebastian.christ@usz.ch.
Gabriel W ThielUniversity of Zurich, Zurich, Switzerland.
Philip HeesenUniversity of Zurich, Zurich, Switzerland.
Siyer RoohaniDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Michael MayingerDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Rämistrasse 100, Zurich, 8091, Switzerland.
Jonas WillmannDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Rämistrasse 100, Zurich, 8091, Switzerland.
Maiwand AhmadseiDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Rämistrasse 100, Zurich, 8091, Switzerland.
Urs J MuehlematterDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Alexander MaurerDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Josef A BuchnerDepartment of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Jan C PeekenDepartment of Radiation Oncology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Rifaquat RahmanDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Brigham & Women's Hospital, Boston, MA, USA.
Ayal AizerDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Brigham & Women's Hospital, Boston, MA, USA.
Emilie Le RhunDepartment of Neurology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Nicolaus AndratschkeDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Rämistrasse 100, Zurich, 8091, Switzerland.
Michael WellerDepartment of Neurology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Martin HuellnerDepartment of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Matthias GuckenbergerDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Rämistrasse 100, Zurich, 8091, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

introductionIncreasing evidence suggests that a subgroup of patients with oligometastatic cancer might achieve a prolonged disease-free survival through local therapy for all active cancer lesions. Our aims are to investigate the impact of brain metastases on the classification, treatment, and outcome in these patients. MATERIALS AND

methodsWe analyzed a total of 7,000 oncological positron emission tomography scans to identify patients with extracranial oligometastatic disease (defined as ≤ 5 intra- or extra-cranial metastases). Concurrent magnetic resonance imaging brain was assessed to quantify intracranial tumor burden. We investigated the impact of brain metastases on oligometastatic disease state, therapeutic approaches, and outcome. Predictors for transitioning from oligo- to polymetastatic states were evaluated using regression analysis.

resultsA total of 106 patients with extracranial oligometastases and simultaneous brain metastases were identified, primarily originating from skin or lung/pleura cancers (90%, n = 96). Brain metastases caused a transition from an extracranial oligometastatic to a whole-body polymetastatic state in 45% (n = 48) of patients. While oligometastatic patients received systemic therapy (55% vs. 35%) more frequently and radiotherapy for brain metastases was more often prescribed to polymetastatic patients (44% vs. 26%), the therapeutic approach did not differ systematically between both sub-groups. The oligometastatic sub-group had a median overall survival of 28 months compared to 10 months in the polymetastatic sub-group (p < 0.01).

conclusionIn patients with brain metastases, a low total tumor burden with an oligometastatic disease state remained a significant prognostic factor for overall survival. Presence of brain metastases should therefore not serve as exclusion criterion for clinical trials in the field of oligometastatic disease. Moreover, it underscores the importance of considering a multimodality treatment strategy in oligometastatic cancer patients.

Indexed as

Brain NeoplasmsAdultAgedAged, 80 and overCross-Sectional StudiesFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedPositron-Emission TomographyPrognosisRetrospective StudiesSurvival RateBrain metastasisOligometastasisTreatment paradigms

Identifiers

PMID39465396
PMCPMC11514885

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.